Ertugliflozin API is an oral hypoglycemic medication that is a member of the sodium-glucose cotransporter 2 inhibitor (SGLT2) class. Patients with type 2 diabetes mellitus (T2DM) mostly utilize it for glycemic control, often as an adjunct therapy when diet and exercise are ineffective. This product was approved by the FDA in 2017 and is included in various combination therapies, such as Segluromet® with metformin and Steglujan® with sitagliptin. Unlike traditional hypoglycemic agents (such as sulfonylureas and insulin), ertugliflozin's hypoglycemic effect is independent of insulin secretion, thus it can also be effective in diabetic patients with impaired pancreatic function. This unique mechanism makes it an important component of modern hypoglycemic therapy.
Shaanxi Medibridge Biotech Co., Ltd. focuses on the supply of pharmaceutical raw materials and research-use compounds. We support customers with stable quality, clear specification communication, flexible packaging options, and document-related support for different project stages.
COA
|
|
||
|
Product Name |
CAS Number |
Batch Number |
|
Ertugliflozin API |
1210344-57-2 |
MB2606130048 |
|
Manufacturer Date |
Analysis Date |
Expiry Date |
|
2026/6/13 |
2026/6/15 |
2028/6/15 |
|
Sample Qty Base |
Packing |
Test Method |
|
100KGS |
25KG/drum |
HPLC |
|
|
||
|
Item |
Standard |
Results |
|
Appearance |
White powder |
Conforms |
|
Identification |
Infrared Spectroscopy(IR)/UV Spectroscopy(UV) Matches reference standard |
Conforms |
|
Assay |
98.0%~102.0% |
99.94% |
|
Loss on drying |
≤0.5% |
0.24% |
|
Residue on ignition |
≤0.1% |
0.05% |
|
Heavy metals |
≤20ppm |
Conforms |
|
Individual impurity |
≤2.0% |
1.15% |
|
Total impurities |
≤5.0% |
2.07% |
|
Microbial Limit |
≤1000cfu/g |
+183° |
|
|
≤100cfu/g |
6.7 |
|
Conclusion |
The batch conforms to the IN-HOUSE standard |
|
|
|
||
Mechanism of Action & Molecular Targets
Ultra-High Selective Inhibition of Renal SGLT2 Transporters
Target Selectivity: Ertugliflozin exhibits over 2,000-fold selectivity for SGLT2 over SGLT1 (primarily expressed in the small intestine and myocardium), ensuring precise inhibition of renal glucose reabsorption while eliminating off-target gastrointestinal adverse effects.
Mechanism of Action: Competitively binds to the SGLT2 transporter in the S1 segment of renal proximal tubules, blocking 30%–50% of filtered glucose and accompanying sodium reabsorption, lowering plasma glucose and inducing natriuretic diuresis.


Restoration of Tubuloglomerular Feedback & Reduction of Intraglomerular Pressure
Increased sodium delivery to the macula densa activates tubuloglomerular feedback, triggering afferent arteriolar constriction to relieve intraglomerular hyperfiltration, hyperperfusion, and physical stress injury.
Metabolic Substrate Switching & Mitochondrial Protection
Induces a fast-like metabolic state, promoting lipolysis and hepatic ketogenesis (e.g., β-hydroxybutyrate). Cardiomyocytes and renal cells utilize ketone bodies as an efficient energy fuel, increasing ATP generation and reducing oxygen consumption.

Kidney Function and Pharmacodynamic Response

An important research question is how systemic exposure and urinary glucose excretion can move in different directions. In the renal-impairment study described in the U.S. product label, ertugliflozin plasma exposure increased as kidney function declined, while 24-hour urinary glucose excretion decreased with greater renal impairment. A higher plasma drug concentration therefore does not necessarily indicate a stronger glucose-excretion response.
Animal and clinical studies should measure kidney function, blood glucose or filtered glucose load, plasma drug concentration, and urinary glucose excretion together. Interpreting pharmacodynamic activity from plasma concentration alone may obscure differences caused by the disease model.
Metabolism, Transporters, and Drug Interactions
Ertugliflozin is cleared primarily through O-glucuronidation mediated by UGT1A9 and UGT2B7, forming two glucuronide metabolites. CYP-mediated oxidative metabolism is a smaller pathway. Ertugliflozin is also a substrate of P-glycoprotein (P-gp) and BCRP. These properties make it useful for studies of glucuronidation, metabolite identification, and membrane transport.
Interaction studies should distinguish enzyme inhibition, enzyme induction, and transporter substrate status. Being a transporter substrate does not, by itself, establish a clinically significant interaction with every inhibitor of that transporter.

Cardiovascular and Kidney Outcome Evidence

VERTIS CV evaluated ertugliflozin in people with type 2 diabetes and established atherosclerotic cardiovascular disease. Its primary composite cardiovascular outcome met the criterion for noninferiority versus placebo; the result should not be described as proof of superiority for reducing major cardiovascular events. Analyses reported a lower risk of first hospitalization for heart failure, while exploratory kidney outcomes provided grounds for further investigation. The status and statistical interpretation of each endpoint should be stated separately.
Safety and Translational Limits
Safety research should address risks related to SGLT2 inhibition. Current U.S. labeling warns about ketoacidosis, volume depletion, urinary tract infections, genital mycotic infections, necrotizing fasciitis of the perineum, and lower-limb amputation. Hypoglycemia also requires attention when ertugliflozin is used with insulin or insulin secretagogues. Ketoacidosis may occur without the degree of hyperglycemia ordinarily expected, so a blood glucose reading alone cannot exclude it.
API and animal studies should relate administered dose to measured systemic exposure, kidney function, fluid status, and ketone-related endpoints. A concentration that appears safe in a selected cell model cannot replace repeated-dose toxicology or an assessment of human risk.

Research Applications & Pharmacological Activities

Type 2 Diabetes & Glucose-Lipid Metabolic Disorders
Widely utilized to evaluate the restoration of pancreatic β-cell function under glucotoxicity, improvements in insulin sensitivity, and the regulation of hepatic gluconeogenesis.
Cardiovascular Protection & Myocardial Remodeling
Employed in myocardial ischemia/reperfusion injury, cardiac hypertrophy, and heart failure models to investigate its efficacy in attenuating myocardial fibrosis, improving endothelial function, and inhibiting vascular smooth muscle cell proliferation.
Diabetic Nephropathy & Renal Fibrosis (CKD)
Applied to assess the reduction of urinary albumin-to-creatinine ratio (UACR), suppression of renal tubular epithelial-mesenchymal transition (EMT), and downregulation of the TGF-β1/Smad signaling pathway.
FAQ
What is the primary molecular target and mechanism of action for Ertugliflozin?
Ertugliflozin is a potent, highly selective SGLT2 inhibitor that reduces renal glucose reabsorption in the proximal convoluted tubule.
What are the main biological research fields for Ertugliflozin API?
It is widely utilized in studies on Type 2 diabetes, metabolic syndrome, diabetic nephropathy, and cardiovascular energetics.
How should Ertugliflozin API be solubilized for in vitro cell-based assays?
It should be dissolved in high-grade DMSO to make a concentrated stock solution prior to diluting into culture media.
What are the recommended storage conditions to ensure the stability of Ertugliflozin API?
The powder should be kept tightly sealed at -20°C in a dry, dark place to protect against thermal and light degradation.
Hot Tags: ertugliflozin api, China ertugliflozin api manufacturers, suppliers, factory, cobicistat active ingredient, cobicistat pharmaceutical excipient blend, dicyclanil veterinary drug substance, mirabegron api, picamilon pharmaceutical powder, prilocaine drug substance



